| Identification | Back Directory | [Name]
JAK1-IN-7 | [CAS]
2241039-81-4 | [Synonyms]
AZD4604
JAK1-IN-7
JAK1IN7,JAK-1-IN-7,JAK1 IN 7 | [Molecular Formula]
C28H31F2N7O4S | [MDL Number]
MFCD32197244 | [MOL File]
2241039-81-4.mol | [Molecular Weight]
599.66 |
| Chemical Properties | Back Directory | [density ]
1.411±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
13.90±0.30(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Londamocitinib (AZD4604) is a potent and selective JAK1 inhibitor with IC50 at 0.54 nM. Londamocitinib has anti-inflammatory activity[1][2][3]. | [in vivo]
Londamocitinib (1 mg/kg, intravenous injection, single dose) can reduce the phosphorylation of STAT3 and STAT5 in the lung of obumin-induced asthmatic rats, inhibit pulmonary eosinophilia, and reduce advanced asthma response in the same model[3].
| Animal Model: | OVA-Induced Rat Model of Asthma[3] | | Dosage: | 1 mg/kg | | Administration: | i.v. | | Result: | Reduced the proportion of phosphorylated STAT3-positive cell nuclei. |
| [IC 50]
JAK1: 0.54 nM (IC50) | [References]
[1] NILSSON, Karl, Magnus, et al. Jak1 selective inhibitors. WO2018134213A1.
[2] Nilsson M, et al. Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization. J Med Chem. 2023 Oct 12;66(19):13400-13415. DOI:10.1021/acs.jmedchem.3c00554
[3] Nilsson M, et al. Characterization of Selective and Potent JAK1 Inhibitors Intended for the Inhaled Treatment of Asthma. Drug Des Devel Ther. 2022 Aug 31;16:2901-2917. DOI:10.2147/DDDT.S354291 |
|
| Company Name: |
ChemCell Biomedicine Co.,Ltd.
|
| Tel: |
020-13556033878 2965585218 13556033878 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15061/0_EN.htm |
|